ciltacabtagene autoleucel
janssen,legend biotech
['multiple myeloma', 'carvykti', 'legn', '$jnj']
carvykti maintains response rates at two years in multiple myeloma patients #asco22 $jnj $legn 
#IME #CME #healthcare #innovation #DotConnector https://t.co/Ag09XUbNP3